November 22, 2024 10:23 AM EST
People
Pharma

Lex­i­con ends com­mer­cial work to fo­cus on R&D

Kyle LaHucik

Senior Reporter

Lex­i­con Phar­ma­ceu­ti­cals is re­vert­ing to a clin­i­cal de­vel­op­ment com­pa­ny af­ter fac­ing re­peat­ed set­backs at the FDA for its type 1 di­a­betes and chron­ic kid­ney dis­ease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times